Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
The bullish case for Nevro Corp (NYSE:NVRO) — a medical device company that focuses on the treatment of chronic pain — no longer applies for three reasons, according to Morgan Stanley.
The Analyst
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Morgan Stanley's David Lewis downgraded Nevro from Overweight to Equal-weight with a price target lowered from $94 to $88.
The Thesis
The bullish case for Nevro's stock was based on the following expectations, Lewis said in a Monday downgrade note:
- Material market share gains.
- An expansion of the total addressable market through new initiatives.
- Clinical superiority for the Senza spinal cord stimulation system.
All three catalysts now hold risk, Lewis said.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
Nevro's commercial message of boasting clinically superior therapies isn't resonating as much as expected, while competing platforms like Abbott Laboratories (NYSE:ABT) Burst and Medtronic PLC (NYSE:MDT)'s Intellis have gained market traction, the analyst said.
Expectations for expansion into new markets not only hasn't occurred, but Nevro is stuck in a "near-term catalyst void," Lewis said, giving the example of the company's diabetic neuropathy and non-surgical back pipelines. After timeline delays, the candidates are slated to begin enrollment in mid-2019, the analyst said.
The superiority of Nevro's Senza could face challenges from Saluda's Evoke system in January 2019 or beforehand, Lewis said. The Saluda platform can be programmed to automatically adjust stimulation levels to a patient's preferred level and could be statistically superior to traditional SCS treatments, negatively affecting Nevro's commercial message, he said.
Price Action
Shares of Nevro were sliding 9.44 percent at the time of publication Monday.
Related Links:
Canaccord: Buy The Dip In Nevro After Disappointing Quarterly Report
Nevro Has A Multi-Billion Dollar Opportunity
Photo courtesy of Nevro Corp.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.